ArticleScientific reports2026
In silico and in vitro assessment of antimicrobial activity of Arctium lappa L. leaf and flower essential oil against WHO priority pathogens.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) poses an escalating global threat, demanding the discovery of innovative therapeutics with novel mechanisms of action. Essential oils (EOs) from medicinal plants are promising candidates due to their multitarget effects and reduced risk of resistance development. This study investigates the chemical profile and antimicrobial mechanisms of essential oil obtained from the aerial parts (leaves and flowers) of Arctium lappa (ALEO), a species with strong ethnopharmacological relevance yet poorly characterized in Tunisia. Gas chromatography–mass spectrometry (GC–MS) revealed 1,3-cyclooctadiene (48.6%), caryophyllene oxide (31.7%), and aromadendrene (12.0%) as major constituents. ALEO demonstrated potent in vitro antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA ATCC 43300), Pseudomonas aeruginosa ATCC 27,853, and Candida auris clinical isolates, with MIC values comparable to reference drugs. Complementary molecular docking identified strong binding affinities of caryophyllene oxide and aromadendrene to bacterial DNA gyrase B and fungal lanosterol 14α-demethylase, while molecular dynamics simulations confirmed stable ligand–protein interactions (RMSD < 2.5 Å) and favorable binding energies (ΔG ≤ − 17 kcal/mol). Together, these findings highlight ALEO as a multitarget antimicrobial agent with therapeutic potential against WHO-priority pathogens, bridging traditional medicinal knowledge and modern drug discovery approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.